Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Wu, ZW; Hu, YL; Xu, M; Chen, Z; Yang, WQ; Jiang, ZW; Li, MJ; Jin, H; Cui, GL; Chen, PP; Wang, L; Zhao, GQ; Ding, YZ; Zhao, YL; Yin, WD

Zhao, YL (corresponding author), Hebei Prov Ctr Dis Control & Prevent, Shijiazhuang 050021, Hebei, Peoples R China.; Yin, WD (corresponding author), Sinovac Biotech, Beijing 100085, Peoples R China.

LANCET INFECTIOUS DISEASES, 2021; 21 (6): 803

Abstract

Background A vaccine against COVID-19 is urgently needed for older adults, in whom morbidity and mortality due to the disease are increased. We aimed ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索